세계의 암배아항원(CEA) 시장 보고서(2025년)

Carcinoembryonic antigen (CEA) is a glycoprotein primarily involved in cell adhesion, commonly found in embryonic tissues and various carcinomas. In clinical practice, CEA serves as a tumor marker crucial for diagnosing, monitoring, and managing cancer, especially colorectal cancer. It aids in evaluating the efficacy of cancer treatments and is used for post-treatment monitoring to detect signs of cancer recurrence.

The main types of carcinoembryonic antigen tests include molecular tests and serology tests. Molecular tests for CEA involve analyzing genetic material, such as DNA or RNA, to measure CEA levels. These tests can be applied across genders, including males and females, and are used in various cancer types such as gastrointestinal cancer, colorectal cancer, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, ovarian cancer, among others. End-users of these tests include hospitals, diagnostic centers, cancer centers, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The carcinoembryonic antigen market research report is one of a series of new reports from The Business Research Company that provides carcinoembryonic antigen market statistics, including the carcinoembryonic antigen industry global market size, regional shares, competitors with the carcinoembryonic antigen market share, detailed carcinoembryonic antigen market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoembryonic antigen industry. These carcinoembryonic antigen market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carcinoembryonic antigen market size has grown rapidly in recent years. It will grow from $1.22 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to cancer prevalence globally, aging population, awareness campaigns, healthcare infrastructure development, and reimbursement policies.

The carcinoembryonic antigen market size is expected to see rapid growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to focus on early detection and prevention, expansion of cancer screening programs, patient demand for personalized medicine, growing demand for minimally invasive diagnostic procedures. Major trends in the forecast period include increased adoption of personalized medicine, technological advancements in diagnostic platforms, integration with artificial intelligence and big data, collaborations and partnerships, and regulatory approvals and reimbursement policies.

The forecast of 12.6% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology monitoring by inflating prices of automated Carcinoembryonic antigen(CEA) assay reagents and Enzyme-linked immunosorbent assay(ELISA) kits developed in Belgium and the Netherlands, resulting in delayed cancer recurrence detection. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the carcinoembryonic antigen market is expected to be driven by an increase in cancer incidence. Cancer, characterized by abnormal cell growth and spread, is on the rise due to various factors such as lifestyle choices, environmental pollution, genetic factors, and an aging population. Carcinoembryonic antigen (CEA) serves as a tumor marker in cancer management, aiding in monitoring disease progression and treatment efficacy. For instance, the World Health Organization (WHO) reported in February 2024 that the predicted number of new cancer cases in 2050 is around 35 million, marking a 77% increase from the estimated 20 million cases in 2022. This surge in cancer cases is a key driver for the carcinoembryonic antigen market's growth.

Major companies in the carcinoembryonic antigen market are increasingly focusing on developing tumor marker tests to improve the testing process and enhance diagnostic capabilities. Tumor marker tests are diagnostic procedures designed to detect specific substances in the body that may indicate the presence of cancer. For example, in July 2023, Roche Diagnostics, a Switzerland-based healthcare diagnostics company, introduced the Elecsys HCV Duo, a dual antigen and antibody diagnostic test that supports India's efforts in combating hepatitis C. This innovative test enables the simultaneous detection of hepatitis C virus (HCV) antigen and antibody status from a single sample, significantly improving early diagnosis of active infections and facilitating timely treatment. The Elecsys HCV Duo helps fill critical diagnostic gaps, especially in high-transmission populations, thereby enhancing the overall effectiveness of hepatitis screening initiatives.

In December 2023, Danaher Corporation acquired Abcam Limited to enhance its capabilities and expand its market presence in life sciences and diagnostics. Abcam Limited, a producer and distributor of protein research tools including recombinant human carcinoembryonic antigen CEA protein, contributes to Danaher's offerings in the field.

Major companies operating in the carcinoembryonic antigen market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilient Technologies, Inc., Beckman Coulter Inc., bioMerieux SA, Quidel Corporation, Ortho Clinical Diagnostics, Abcam plc, RayBiotech Inc., Creative Diagnostics, Lee Biosolutions Inc., Hytest Ltd., Prospec-Tany Technogene Ltd, Boster Biological Technology, Metropolis Healthcare

North America was the largest region in the carcinoembryonic antigen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the carcinoembryonic antigen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carcinoembryonic antigen market consists of sales of diagnostic kits or assays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carcinoembryonic Antigen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carcinoembryonic antigen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carcinoembryonic antigen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The carcinoembryonic antigen market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Molecular Tests; Serology Tests
• 2) By Gender: Male; Female
• 3) By Application: Gastrointestinal Cancer; Colorectal Cancer; Pancreatic Cancer; Breast Cancer; Lung Cancer; Thyroid Cancer; Ovarian Cancer; Other Applications
• 4) By End User: Hospitals; Diagnostic Centers; Cancer Centers; Research And Academic Institutes
• Subsegments:
• 1) By Molecular Tests: Polymerase Chain Reaction (PCR); Reverse Transcription PCR (RT-PCR); Next-Generation Sequencing (NGS); Fluorescence In Situ Hybridization (FISH); Gene Expression Profiling
• 2) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA); Chemiluminescent Immunoassay (CLIA); Radioimmunoassay (RIA); Immunohistochemistry (IHC); Lateral Flow Assays
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Merck KGaA; Siemens Healthineers; Laboratory Corporation of America Holdings; Quest Diagnostics; Agilient Technologies, Inc.; Beckman Coulter Inc.; bioMerieux SA; Quidel Corporation; Ortho Clinical Diagnostics; Abcam plc; RayBiotech Inc.; Creative Diagnostics; Lee Biosolutions Inc.; Hytest Ltd.; Prospec-Tany Technogene Ltd; Boster Biological Technology; Metropolis Healthcare
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Carcinoembryonic Antigen market Characteristics

3. Carcinoembryonic Antigen market Trends And Strategies

4. Carcinoembryonic Antigen market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Carcinoembryonic Antigen Growth Analysis And Strategic Analysis Framework

• 5.1. Global Carcinoembryonic Antigen PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Carcinoembryonic Antigen market Growth Rate Analysis
• 5.4. Global Carcinoembryonic Antigen Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Carcinoembryonic Antigen Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Carcinoembryonic Antigen Total Addressable Market (TAM)

6. Carcinoembryonic Antigen market Segmentation

• 6.1. Global Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Molecular Tests
• Serology Tests
• 6.2. Global Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Male
• Female
• 6.3. Global Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrointestinal Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Breast Cancer
• Lung Cancer
• Thyroid Cancer
• Ovarian Cancer
• Other Applications
• 6.4. Global Carcinoembryonic Antigen market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Cancer Centers
• Research And Academic Institutes
• 6.5. Global Carcinoembryonic Antigen Market, Sub-Segmentation Of Molecular Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)
• Reverse Transcription PCR (RT-PCR)
• Next-Generation Sequencing (NGS)
• Fluorescence In Situ Hybridization (FISH)
• Gene Expression Profiling
• 6.6. Global Carcinoembryonic Antigen Market, Sub-Segmentation Of Serology Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chemiluminescent Immunoassay (CLIA)
• Radioimmunoassay (RIA)
• Immunohistochemistry (IHC)
• Lateral Flow Assays

7. Carcinoembryonic Antigen market Regional And Country Analysis

• 7.1. Global Carcinoembryonic Antigen market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Carcinoembryonic Antigen market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Carcinoembryonic Antigen market

• 8.1. Asia-Pacific Carcinoembryonic Antigen market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Carcinoembryonic Antigen market

• 9.1. China Carcinoembryonic Antigen market Overview
• 9.2. China Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Carcinoembryonic Antigen market

• 10.1. India Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Carcinoembryonic Antigen market

• 11.1. Japan Carcinoembryonic Antigen market Overview
• 11.2. Japan Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Carcinoembryonic Antigen market

• 12.1. Australia Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Carcinoembryonic Antigen market

• 13.1. Indonesia Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Carcinoembryonic Antigen market

• 14.1. South Korea Carcinoembryonic Antigen market Overview
• 14.2. South Korea Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Carcinoembryonic Antigen market

• 15.1. Western Europe Carcinoembryonic Antigen market Overview
• 15.2. Western Europe Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Carcinoembryonic Antigen market

• 16.1. UK Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Carcinoembryonic Antigen market

• 17.1. Germany Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Carcinoembryonic Antigen market

• 18.1. France Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Carcinoembryonic Antigen market

• 19.1. Italy Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Carcinoembryonic Antigen market

• 20.1. Spain Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Carcinoembryonic Antigen market

• 21.1. Eastern Europe Carcinoembryonic Antigen market Overview
• 21.2. Eastern Europe Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Carcinoembryonic Antigen market

• 22.1. Russia Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Carcinoembryonic Antigen market

• 23.1. North America Carcinoembryonic Antigen market Overview
• 23.2. North America Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Carcinoembryonic Antigen market

• 24.1. USA Carcinoembryonic Antigen market Overview
• 24.2. USA Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Carcinoembryonic Antigen market

• 25.1. Canada Carcinoembryonic Antigen market Overview
• 25.2. Canada Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Carcinoembryonic Antigen market

• 26.1. South America Carcinoembryonic Antigen market Overview
• 26.2. South America Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Carcinoembryonic Antigen market

• 27.1. Brazil Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Carcinoembryonic Antigen market

• 28.1. Middle East Carcinoembryonic Antigen market Overview
• 28.2. Middle East Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Carcinoembryonic Antigen market

• 29.1. Africa Carcinoembryonic Antigen market Overview
• 29.2. Africa Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Carcinoembryonic Antigen market Competitive Landscape And Company Profiles

• 30.1. Carcinoembryonic Antigen market Competitive Landscape
• 30.2. Carcinoembryonic Antigen market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

31. Carcinoembryonic Antigen market Other Major And Innovative Companies

• 31.1. Laboratory Corporation of America Holdings
• 31.2. Quest Diagnostics
• 31.3. Agilent Technologies, Inc.
• 31.4. Beckman Coulter Inc.
• 31.5. bioMerieux SA
• 31.6. Quidel Corporation
• 31.7. Ortho Clinical Diagnostics
• 31.8. Abcam plc
• 31.9. RayBiotech Inc.
• 31.10. Creative Diagnostics
• 31.11. Lee Biosolutions Inc.
• 31.12. Hytest Ltd.
• 31.13. Prospec-Tany Technogene Ltd
• 31.14. Boster Biological Technology
• 31.15. Metropolis Healthcare

32. Global Carcinoembryonic Antigen market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Carcinoembryonic Antigen market

34. Recent Developments In The Carcinoembryonic Antigen market

35. Carcinoembryonic Antigen market High Potential Countries, Segments and Strategies

• 35.1 Carcinoembryonic Antigen market In 2029 - Countries Offering Most New Opportunities
• 35.2 Carcinoembryonic Antigen market In 2029 - Segments Offering Most New Opportunities
• 35.3 Carcinoembryonic Antigen market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer